[Federal Register Volume 59, Number 157 (Tuesday, August 16, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-19937]


[[Page Unknown]]

[Federal Register: August 16, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Partially Exclusive Licenses: Inhibition of 
Cell Proliferation Using Antisense Oligonucleotides

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
partially exclusive world-wide licenses to practice the invention 
embodied in U.S. Patent Applications SN 07/821,415 and 08/187,785, both 
entitled ``Inhibition of Cell Proliferation Using Antisense 
Oligonucleotides'' to Lynx Therapeutics, Inc. of Hayward, California 
and to Genta Incorporated of San Diego, California jointly with CV 
Therapeutics, Inc. of Mountain View, California. The patent rights in 
this invention have been assigned to the United States of America.
    The prospective partially exclusive licenses will be royalty-
bearing and will comply with the terms and conditions of 35 U.S.C. 209 
and 37 CFR 404.7. These prospective partially exclusive licenses may be 
granted unless within 60 days from the date of this published notice, 
NIH receives written evidence and argument that establishes that the 
grant of the licenses would not be consistent with the requirements of 
35 U.S.C. 209 and 37 CFR 404.7.
    The patent applications disclose a novel strategy that uses 
antisense oligonucleotides to prevent the renarrowing of heart valves 
or peripheral vessels (i.e., restenosis) following coronary balloon 
angioplasty. The antisense oligonucleotides employed inhibit the 
proliferation of the smooth muscle cells (SMCs) that cause restenosis 
by targeting specific mRNAs that encode certain cell cycle regulatory 
proteins. The oligonucleotides are delivered locally via the slow 
biodegradation of polymers that have been saturated with the 
antiproliferative compounds.

ADDRESSES: Requests for copies of these patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: Mr. Arthur J. Cohn, Esq., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20892-
3804. Telephone: (301) 496-7735 ext. 284; Facsimile: (301) 402-0220. A 
signed Confidentiality Agreement will be required to receive copies of 
the patent applications. Applications for a license in the any field of 
use filed in response to this notice will be treated as objections to 
the grant of the contemplated licenses. Only written comments and/or 
applications for a license which are received by NIH within sixty (60) 
days of this notice will be considered.

    Dated: August 9, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-19937 Filed 8-15-94; 8:45 am]
BILLING CODE 4140-01-P